Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;26(5):898-908.
doi: 10.2174/0929867324666171012105528.

Biomarkers of Atrial Fibrillation in Metabolic Syndrome

Christos Georgakopoulos  1 , Charalambos Vlachopoulos  1 , Georgios Lazaros  1 , Dimitrios Tousoulis  1
Affiliations
Review

Biomarkers of Atrial Fibrillation in Metabolic Syndrome

Christos Georgakopoulos et al. Curr Med Chem. 2019.

Abstract

Whether the increased atrial fibrillation (AF) risk in metabolic syndrome (MetS) patients is due to the syndrome as a whole or simply the sum of the risks of its individual component parts is still obscure. These two clinical entities share many pathophysiological links and thus distinction between a casual observation and a significant association is difficult. Biomarkers associated with pathogenesis of AF in the context of MetS have the ability to refine future risk prediction. In the present review we identify circulating substances that could be regarded as potential biomarkers for prediction of incident AF, or of cardiovascular events in the setting of AF in patients with MetS. Cardiac myocyte injury and stress markers (troponin and natriuretic peptides), markers of renal function (glomeral filtration rate, cystatin-C), and inflammation markers/mediators (interleukin- 6, CRP) are promising biomarkers of patients with AF and MetS.

Keywords: Atrial fibrillation; BNP; Biomarkers; CRP; Cystatin-C; GFR; IL-6; Inflammation; Kidney disease; Metabolic Syndrome; Troponin..

PubMed Disclaimer